Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Almirall ( (ES:ALM) ) is now available.
Almirall has convened its Ordinary General Shareholders’ Meeting for 8 May 2026 in Barcelona, with a second-call date set for 9 May if quorum is not reached. Shareholders will be asked to approve the company’s and group’s 2025 financial statements, non-financial and sustainability reporting, management performance, and the allocation of results, including a proposed dividend distribution from freely distributable reserves.
The agenda also includes amendments to several articles of the Articles of Association and the General Shareholders’ Meeting Regulations, covering bond issuance, board term limits, meeting calls, and the audit committee’s role. In addition, the company plans to reshape its board by accepting a director’s resignation, setting the board at ten members, re-electing two independent directors, and appointing a new independent director, alongside a bonus share capital increase charged to voluntary reserves, with new shares to be listed on the Spanish stock exchanges.
The most recent analyst rating on (ES:ALM) stock is a Buy with a EUR12.50 price target. To see the full list of analyst forecasts on Almirall stock, see the ES:ALM Stock Forecast page.
More about Almirall
Almirall, S.A. is a Spanish pharmaceutical company focused on developing and marketing prescription medicines. The company operates globally with a particular emphasis on dermatology and other specialty therapeutic areas, supplying treatments that target unmet medical needs in its core markets.
Average Trading Volume: 161,381
Technical Sentiment Signal: Strong Buy
Current Market Cap: €2.59B
For a thorough assessment of ALM stock, go to TipRanks’ Stock Analysis page.